Manon Girard

Sotagliflozin, a dual sodium‐glucose co‐transporter‐1 and sodium‐glucose co‐transporter‐2 inhibitor, reduces the risk of cardiovascular and kidney disease, as assessed by the Steno T1 Risk Engine in adults with type 1 diabetes

P. Rossing, F. Persson, P. Banks, 2023, Diabetes, obesity & metabolism.